Literature DB >> 29193105

Correlations between cystic fibrosis genotype and sinus disease severity in chronic rhinosinusitis.

Waleed M Abuzeid1, Changeun Song2,3, Judd H Fastenberg1, Christina H Fang1, Noel Ayoub2, Elina Jerschow4, Paul K Mohabir5, Peter H Hwang2.   

Abstract

OBJECTIVE: Cystic fibrosis (CF) patients commonly develop chronic rhinosinusitis (CRS). The impact of the most common cystic fibrosis transmembrane conductance regulator (CFTR) mutation, F508del, on the severity of sinonasal disease remains inconclusive. The objective of this study is to evaluate the impact of CFTR genotype functional classification on sinonasal disease severity in patients with CRS.
METHODS: Retrospective chart review of patients with CF who underwent endoscopic sinus surgery for chronic rhinosinusitis from 1998 to 2015. Patients were divided into high- or low-risk genotypes based on standardized CFTR gene functional classification. The primary outcome was the 22-item Sino-Nasal Outcome Test (SNOT-22) score. Secondary outcomes included endoscopic scores, extent of surgery performed, presence of polyposis, number of revision surgeries, and Lund-MacKay computed tomography scores.
RESULTS: Thirty-eight patients harbored a high-risk CFTR genotype, and 11 had a low-risk genotype. On bivariate analysis, there was no association between CFTR genotype risk stratification and measures of preoperative disease severity or postoperative outcomes. There were no associations between genotype risk stratification and outcome variables on multivariate linear regression, adjusted for age and gender. There were significant improvements in several SNOT-22 subdomains before and after endoscopic sinus surgery (P < 0.05), but the magnitude of improvement was not significantly different on the basis of CFTR genotype risk stratification.
CONCLUSION: High-risk CFTR genotypes are not associated with worse sinonasal disease severity or postoperative symptom control than low-risk CFTR genotypes after adjusting for confounding factors. LEVEL OF EVIDENCE: Level 4. Laryngoscope, 1752-1758, 2018.
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Cystic fibrosis; genotype; outcome assessment (health care); quality of life; sinusitis

Mesh:

Substances:

Year:  2017        PMID: 29193105     DOI: 10.1002/lary.27019

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.

Authors:  Matt Lechner; Yoko Takahashi; Mario Turri-Zanoni; Jacklyn Liu; Nicholas Counsell; Mario Hermsen; Raman Preet Kaur; Tianna Zhao; Murugappan Ramanathan; Volker H Schartinger; Oscar Emanuel; Sam Helman; Jordan Varghese; Jozsef Dudas; Herbert Riechelmann; Susanne Sprung; Johannes Haybaeck; David Howard; Nils Wolfgang Engel; Sarah Stewart; Laura Brooks; Jessica C Pickles; Thomas S Jacques; Tim R Fenton; Luke Williams; Francis M Vaz; Paul O'Flynn; Paul Stimpson; Simon Wang; S Alam Hannan; Samit Unadkat; Jonathan Hughes; Raghav Dwivedi; Cillian T Forde; Premjit Randhawa; Simon Gane; Jonathan Joseph; Peter J Andrews; Gary Royle; Alessandro Franchi; Roberta Maragliano; Simonetta Battocchio; Helen Bewicke-Copley; Christodoulos Pipinikas; Amy Webster; Chrissie Thirlwell; Debbie Ho; Andrew Teschendorff; Tianyu Zhu; Christopher D Steele; Nischalan Pillay; Bart Vanhaesebroeck; Ahmed Mohyeldin; Juan Fernandez-Miranda; Ki Wan Park; Quynh-Thu Le; Robert B West; Rami Saade; R Peter Manes; Sacit Bulent Omay; Eugenia M Vining; Benjamin L Judson; Wendell G Yarbrough; Maddalena Sansovini; Nicolini Silvia; Ilaria Grassi; Alberto Bongiovanni; David Capper; Ulrich Schüller; Selvam Thavaraj; Ann Sandison; Pavol Surda; Claire Hopkins; Marco Ferrari; Davide Mattavelli; Vittorio Rampinelli; Fabio Facchetti; Piero Nicolai; Paolo Bossi; Oswaldo A Henriquez; Kelly Magliocca; C Arturo Solares; Sarah K Wise; Jose L Llorente; Zara M Patel; Jayakar V Nayak; Peter H Hwang; Peter D Lacy; Robbie Woods; James P O'Neill; Amrita Jay; Dawn Carnell; Martin D Forster; Masaru Ishii; Nyall R London; Diana M Bell; Gary L Gallia; Paolo Castelnuovo; Stefano Severi; Valerie J Lund; Ehab Y Hanna
Journal:  Eur J Cancer       Date:  2021-12-31       Impact factor: 10.002

2.  Predictors of sinonasal disease onset, progression, and severity in pediatric cystic fibrosis patients.

Authors:  Michael S Weinstock; Amber D Shaffer; Amanda L Stapleton
Journal:  Am J Otolaryngol       Date:  2021-03-31       Impact factor: 2.873

3.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

Review 4.  Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options.

Authors:  Joanna Krajewska; Krzysztof Zub; Adam Słowikowski; Tomasz Zatoński
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-22       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.